N/A N=12 The Fasting II Study
Diabetes · Metabolic Diseases
Primary: Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week. — 104.7; 104.5 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=105 Effects of Fast Bar on Physiological Fasting
Fasting
Primary: Ketone Area Under the Curve — 1.27; 0.62; 1.17 mg/dL*h
N/A N=60 The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy
Excessive Diet Restriction
Primary: Insulin Sensitivity (HOMA-IR) — 0.05; 0.06 no unit
N/A N=88 Prolonged Daily Fasting as a Viable Alternative to Caloric Restriction in At-Risk Obese Humans
Obesity
Primary: Change in Weight — -3; -3.5; -1.3 Kg
N/A N=30 Expression of Longevity Genes in Response to Extended Fasting
Cardiovascular Disease
Primary: Change From Baseline in Participant Glucose When Fasting and Fed — 83.3; -8.0; 5.9 mg/dL
N/A N=77 Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
Long Covid19 · Long COVID
Primary: Change in LC-Score, Per Treatment — -10.2; -2.8 Scores on a Scale
N/A N=55 Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Intermittent Fasting · Metabolic Dysfunction-Associated Fatty Liver Disease
Primary: Transient Elastography-Controlled Attenuation Parameter — 319.5; 343.5; 291.5; 285.0 db/m
N/A N=80 Alternate Day Fasting, Exercise, and NAFLD
Non-Alcoholic Fatty Liver Disease · Obesity
Primary: Change in Hepatic Steatosis — -2.25; -1.3; -5.48; -0.17 liver fat percentage
N/A N=200 Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy
Gestational Diabetes · Diagnoses Disease · Pregnancy in Diabetic
Primary: Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT) — 31; 13…
N/A N=100 Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection
Coronary Heart Disease · Obesity · Weight Loss
Primary: Body Weight — -4.6; -4.5; 0.3 Percent change at month 12
N/A N=37 Intermittent Fasting Adherence and Self Tracking
Hypertension · Obesity
Primary: Adherence to the Intermittent Fasting Regimen, Captured Via Daily Text Message, Over 18 Weeks, Expressed in Days Per Week — 4.7; 5.4 days per week
N/A N=60 Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
Fatty Liver Disease · Type 2 Diabetes · Impaired Glucose Regulation
Primary: Change of Liver Fat Content in % — -20.5; -15.5; -7.6; -7.3 absolute fat content change in %
Phase 1 N=10 Study to Evaluate Potential Food Effects
Healthy
Primary: Cmax — 2567.9; 3568.9 ng/mL
Phase 2 N=10 Almond Butter and Fasting Glucose
Type2 Diabetes
Primary: Fasting Glucose Measured Using Continuous Glucose Monitoring — 148.6; 142.1 mg/dL
N/A N=50 Time Limited Eating in Adolescents (Time LEAd): a Pilot Study
Obesity, Childhood
Primary: Percent Change in BMI in Excess of the 95th Percentile (%BMIp95) — -3.27; -3.76; -4.85 percent — p=0.4
N/A N=100 Self-Control in Bulimia Nervosa
Bulimia Nervosa
Primary: Brain Activation Associated With P(Stop) — 0.02; 0.11; 0.04; 0.05 BOLD Signal
Phase 2 N=13 Role of Leptin in the Neuroendocrine and Immune Response to Fasting
Fasting
Primary: Cortisol — 17.5; 16.9 ug/dl
N/A N=64 TRE in Type 2 Diabetes (See Food Study 3)
Type2Diabetes
Primary: Change in Glycemic Measures- HbA1c (12w) — -0.22; -0.25 percentage of glycated hemoglobin
N/A N=74 A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
Migraine
Primary: Incidence of Fasting-induced Headache of Any Intensity — 12; 18 participants — p=0.172
Phase 3 N=870 Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With at Least One Symptomatic Hypoglycemic Event — 3.8; 7.3 percentage of participants — p=0.028
Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
N/A N=6 Time Restricted Eating Pilot - Bariatrics
Time Restricted Feeding
Primary: Weight — -.07 kg
N/A N=50 Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Progression-free-survival — 20; 16 percentage of participants
Phase 1 N=34 Fasting Bioavailability Study of Zonisamide Capsules
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 1,052.65; 1,078.46 ng/mL
N/A N=29 Time Restricted Eating on Cancer Risk
Pre-diabetes · Breast Cancer · Time Restricted Feeding
Primary: Change in Advanced Glycation End Products (AGE) as Assessed by Plasma — 5.82; 6.38; 5.82; 6.40 ng/mL
N/A N=28 Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Feasibility to Enroll and Retain Participants — 122 Participants
N/A N=33 Time Restricted Eating for Metabolic and Psychological Optimization
Mild Cognitive Impairment · Obesity
Primary: Change in Memory Composite Rank — 6.22 rank — p=<0.001
Phase 1 N=15 Pharmacokinetics of Leptin Administration During Fasting
Energy Deficiency Due to Short-term Fasting
Primary: Leptin Pharmacokinetic Parameters - TIME(T1/2) DAY 3 / TMAX DAY 3 72-hour Fasting Day 3 Leptin Dose 0.01 mg/kg — 1.93; 2.75; 2.99; 2.00 HR
Phase 4 N=1,066 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
Type 2 Diabetes Mellitus (T2DM)
Primary: Proportion of Participants With at Least One Symptomatic Hypoglycemic Event — 0.07; 0.13 proportion of participants — p=0.0005
N/A N=22 Impact of Meal Timing on Glycemic Profile in Latino Adolescents With Obesity
Pediatric Obesity · Meal Timing
Primary: Change in Insulinogenic Index From Baseline After Test Meal From Venous Sample — 268; 215; 153 Microunits per milliliter